SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-20-101135
Filing Date
2020-04-08
Accepted
2020-04-08 13:54:57
Documents
2
Group Members
MPM ONCOLOGY IMPACT MANAGEMENT GP LLCMPM ONCOLOGY IMPACT MANAGEMENT LPONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d113485dsc13ga.htm SC 13G/A 112278
2 EX-99.A d113485dex99a.htm EX-99.A 21415
  Complete submission text file 0001193125-20-101135.txt   135350
Mailing Address 35 PARKWOOD DRIVE SUITE 210 HOPKINTON MA 01748
Business Address 35 PARKWOOD DRIVE SUITE 210 HOPKINTON MA 01748 508-473-5993 X119
Spring Bank Pharmaceuticals, Inc. (Subject) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-89626 | Film No.: 20781722
SIC: 2834 Pharmaceutical Preparations

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Filed by) CIK: 0001691428 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G/A